AMAG Pharmaceuticals — Merger or Acquisition (June 2015)
15 slides from AMAG Pharmaceuticals's merger presentation, Jun 29, 2015
Slide 1: AMAG to Acquire Cord Blood Registry
AMAG to Acquire Cord Blood Registry® June 29, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including among others, state
Slide 3: Strategic Rationale
Strong Financial profile, management team & corporate infrastructure Strategic Rationale Acquisition of Cord Blood Registry is another step in AMAG’s growth and diversification strategy focused on high-value specialty segments 2 FUTURE PRODUCT Maternal Health Hematology/Oncology, Hospital, Nephrolog
Slide 4: Acquisition Highlights
Acquisition Highlights Complementary business expands AMAG’s maternal health platform World’s largest stem cell collection and storage company #1 stem cell banking brand with healthcare providers and customers Favorable market conditions and large addressable market Strong strategic and commercial f
Slide 5: Transaction Terms
Transaction Terms 4 Transaction Structure Operational Structure Committed Financing Timing $700MM purchase price, payable in cash (~11x EBITDA)1 Funded through combination of AMAG’s existing cash and new capital CBR CEO Geoffrey Crouse will join AMAG and continue to lead CBR business Expanded physic
Slide 6: About Cord Blood Registry
About Cord Blood Registry 5 Overview Founded in 1992; HQ in San Bruno, CA Currently stores more than 600,000 preserved umbilical cord blood and cord tissue stem cell units and growing Helps more families than any other family cord blood company use privately banked cord blood for established and inv
Slide 7: Industry-Leading Growth Business
CBR has banked over half of all privately stored cord units in U.S. More new clients per year than three largest competitors combined High customer loyalty; <1% annual attrition rate Consistent double-digit growth of installed base Industry-Leading Growth Business 6 6 CBR Total Active Units In Stora
Slide 8: Favorable Market Dynamics
Favorable Market Dynamics 7 4 million births annually and growing Cord blood from fewer than 5% of births banked in U.S. Rebounding consumer economy Increased awareness and interest in stem cell research Proactive, informed consumers Consumers increasing willingness to pay cash for healthcare costs
Slide 9: Commitment to Stem Cell Science
Commitment to Stem Cell Science 8 Over 100,000 families currently enrolled and growing Capability to provide families with clinically relevant data (research and published findings) Initial conditions targeted are: Cerebral Palsy and Static Encephalopathies Autism and Apraxia Hearing Loss Type I Dia
Slide 10: Enhanced Commercial Capabilities
Enhanced Commercial Capabilities 9 Increased Healthcare Provider Sales Effort Sophisticated Consumer Marketing Strengthens platform with broader product offering to obstetricians and pregnant mothers/families Expands reach to more obstetricians Leverages long-standing relationships with medical comm
Slide 11: Financially Compelling Transaction
Financially Compelling Transaction 10 Net Revenue ($MM) Adjusted EBITDA ($MM) 1 2015 projected net revenue and adjusted EBITDA assume midpoint of AMAG’s 2015 financial guidance. 2 2015 estimated pro forma net revenue and adjusted EBITDA assume consummation of CBR at the beginning of 2015. 3 Synergiz
Slide 12: CBR: Another Step in AMAG's Growth & Diversification Strategy
11 CBR: Another Step in AMAG’s Growth & Diversification Strategy $500MM 2015 Estimated Pro Forma Revenue1 Addition of complementary, growing business expands AMAG’s maternal health platform ----- Strong strategic and commercial fit ----- Financially compelling 1 2015 estimated pro forma revenue assu
Slide 13: AMAG to Acquire Cord Blood Registry
AMAG to Acquire Cord Blood Registry® June 29, 2015
Slide 14: Appendix
Appendix Qyamag
Slide 15: Reconciliation Tables
Reconciliation Tables (Unaudited; amounts in thousands) Reconciliation of 2014 Non-GAAP Revenue 2014 GAAP net revenue $121,790 2012 purchase accounting deferred revenue impact 4,386 Pro forma net revenue $126,176 14 Reconciliation of 2014 Non-GAAP Adjusted EBITDA 2014 GAAP net income (loss) $(15,136
Amag Pharmaceuticals — Merger or Acquisition (June 2015) on 6ix